ICAM1 and pachyonychia congenita: We have demonstrated that by conjugating an anticancer drug with the active targeting ICAM1 antibody, we could effectively and specifically deliver this drug into PC tumors via ICAM1 antibody guidance while limiting the distribution to normal organs/tissues, which in turn, reduces off target toxicities.